Clinical Report: A CD4+ T cell subset associated with CXCL13 is the primary source of IL21

Overview

This study identifies CXCL13-associated CD4+ T cells as the primary source of IL21 in colorectal cancer. The findings link this cytokine to an immune-active tumor microenvironment.

Background

Colorectal cancer (CRC) is a prevalent malignancy with significant clinical implications. Understanding the immune microenvironment, particularly the role of T cell subsets, is crucial for improving therapeutic strategies in the context of immunotherapy. IL21 has emerged as a cytokine in CRC, yet its specific sources and functions are not fully elucidated.

Data Highlights

No numerical data available in the source material.

Key Findings

• IL21 expression is predominantly found in a limited fraction of tumor-infiltrating CD4+ T cells, particularly in CXCL13+CD4+ T cell populations.
• Multiplex immunofluorescence confirmed increased levels of IL21 and IL21+CD4+ T cells in tumor tissues compared to adjacent normal tissues.
• Correlation analysis indicated a positive association between IL21 expression and various CD4+ T cell populations.
• SCENIC analysis identified key transcription factors associated with the CXCL13+CD4+ T cell subset.
• Exogenous IL21 induced significant transcriptional changes in murine colorectal tumor tissues, activating immune-related pathways.

Clinical Implications

The identification of CXCL13-associated CD4+ T cells as a source of IL21 may inform future research on immune modulation in colorectal cancer.

Conclusion

This study provides insights into the cellular sources of IL21 in colorectal cancer, emphasizing the role of specific T cell subsets.

Related Resources & Content

1. Frontiers | IL21 Is Predominantly Produced by a CXCL13 Associated CD4+ T Cell Subset and Shapes the Immune Microenvironment in Colorectal Cancer
2. The ASCO Post — IL-17A Promotes and GM-CSF Suppresses Circulating Tumor Cells and Metastasis in Colorectal Cancer
3. Journal of Gastroenterology — Significance of the IL-22 Pathway in Inflammatory Bowel Disease
4. Frontiers in Immunology — Plasticity and antigen presentation by group 3 innate lymphoid cells in colorectal cancer
5. Frontiers in Immunology — Cytokine and chemokine networks in colorectal cancer
6. 2026 NCCN Clinical Practice Guidelines in Oncology®: Key Updates Across Tumor Types - The ASCO Post
7. Immunotherapy Combo Approved for dMMR Colorectal Cancer - NCI
8. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial - PubMed
9. Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions | American Society of Clinical Oncology Educational Book
10. ‘Triple-Punch’ Combo Therapy Slows Progressions of Some Metastatic Colorectal Cancers - ASCO
11. COMMIT First-Line Atezolizumab Plus FOLFOX and Bevacizumab Regimen in Metastatic Colorectal Cancer - The ASCO Post
12. First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW. | Journal of Clinical Oncology
13. The immune microenvironment of colorectal cancer | Nature Reviews Cancer
14. Tertiary lymphoid structures signature predicts prognosis and clinical benefits from neoadjuvant chemotherapy and PD-1 blockade in colorectal adenocarcinoma - PubMed
15. The predictive value of intratumoral tertiary lymphoid structures on the response to immunotherapy in cancer patients: a systematic review and meta-analysis - PubMed
16. CXCL13 as a Prognostic Biomarker and Modulator of the Tumor Microenvironment in Colorectal Cancer - PubMed
17. Frontiers | IL21 Is Predominantly Produced by a CXCL13 Associated CD4+ T Cell Subset and Shapes the Immune Microenvironment in Colorectal Cancer